PharmaBoardroom

Prof Dr Jürg Utzinger of the Swiss Tropical and Public Health Institute (Swiss TPH) outlines the organisation’s important role within the global…

Innosuisse CEO Annalise Eggimann presents the organisation’s renewed mandate as the main Swiss innovation promotion agency, how Innosuisse serves…

Joe Lewis outlines the key concerns of Deloitte’s pharma clients around manufacturing and supply chain operations in the wake of the COVID-19…

PharmaBoardroom had the pleasure of interviewing HitGen chairman & CEO Dr Jin LI in July regarding the company’s focus on DNA-encoded chemical…

Dennis Hens, the Dutch CEO of Norwegian neuro-opthalmology device player Bulbitech, outlines the company’s journey to market, how its technology can…

Ipsen CEO David Loew took aim at the lip service often paid to the notion of ‘patient-centricity’ in pharma in conversation at the FT’s Global…

During the FT Global Pharmaceutical and Biotechnology Conference earlier this week, four Big Pharma and biotech executives spoke about the changing…

Clint Sharples, CEO of Heritage Cannabis, gives a potted history of the medical cannabis industry in Canada, its current legal status, provincial…

PharmaBoardroom highlights three of the most enterprising and dynamic pharma affiliate country managers working in Switzerland today and their…

When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to leave the European Union, some…

Sandoz Switzerland’s Jan Tangermann highlights the importance of the Swiss affiliate to the global group and how it was able to provide sustainable…

Thomas Bohn outlines how the life sciences industry in Western Switzerland has continued to perform well despite the COVID-19 pandemic, highlights…